News

Lighthouse Labs Announces Newest Cohort

The three Richmond businesses will join six others — including two from elsewhere in Virginia — as part of the 12th cohort of businesses to go through Lighthouse Labs, a program that provides mentoring, advice and financial support to promising startup businesses.

This year marks the 10th year that Lighthouse Labs has operated. Including this spring’s cohort, Lighthouse Labs has worked with 89 companies and more than 160 founders.

“Over the course of the last decade, we’ve attracted some of the most talented founders and mentors to the Richmond startup community,” said Erin Powell, executive director of Lighthouse Labs. “The support for growing our startup ecosystem here in Richmond has been growing steadily for the last few years.”

The spring 2022 cohort will meet for regularly for 12 weeks starting March 7, and will get mentoring from numerous volunteers and advisory services from Lighthouse Labs’ partners such as Global Accelerator Network, Kaleo Legal, Sandbox and Startup Virginia.

Lighthouse received more than 160 applications for the nine spots in the upcoming cohort.

Five of the nine companies are in Virginia. Two are based in Pennsylvania and two based in Texas.

Six of the nine teams are in the healthcare industry. “There is a lot of focus on healthcare,” said Powell, adding that Lighthouse Labs continues to partner with a consortium of health providers including Virginia Commonwealth University to help bring health innovations to market.

Companies participating in the program also get $20,000 of equity-free funding.

The companies in the spring 2022 cohort are:

Llamawood,

  • a Richmond-based on-demand firewood delivery platform;

LipLoveLine,

  • a Richmond-based ingredient-conscious lip care brand;

Nessle,

  • a Richmond-based online platform that connects new and expectant parents to perinatal experts for on-demand care;

Transfoam,

  • A Charlottesville-based biotechnology firm using engineered microorganisms to turn waste into biodegradable plastic alternatives

Kinometrix,

  • a Fort Belvoir-based developer of an artificial intelligence platform to enhance patient safety in hospitals;

On Time Trials,

  • a Round Rock, Texas, software company using machine learning to optimize clinical trial monitoring;

Hoth Intelligence,

  • a Philadelphia company that provides augmented reality solutions for medical problems;

Viora,

  • a Philadelphia company that reduces health risks due to social and behavioral determinants, and

CaseCTRL,

  • a Houston-based software developer of surgical case management systems.

Learn more here.

Recent News

02/05/2025

Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences

The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge),

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who